CA-G2-RISK-SOLUTIONS
27.8.2024 15:08:33 CEST | Business Wire | Press release
G2 Risk Solutions (G2RS), the global leader in risk and compliance business intelligence, today celebrates the release of the API version of its cornerstone product, advancing its vision to simplify and optimize merchant risk management for acquiring banks and payments facilitators. Global Onboarding, an AI-powered merchant onboarding solution, helps users safely onboard new merchants quickly with highly accurate predictive risk assessments.
One solution to manage it all
Global Onboarding is the final building block in a unified solution that integrates onboarding seamlessly with G2RS monitoring products, Persistent Merchant Monitoring and Transaction Laundering Detection. For the first time, risk managers have the ability within a single platform to underwrite merchants, approve them intelligently at scale, and then usher the flow of approved merchants in and out of activities that continuously monitor for a wide variety of illegal and/or violative conduct.
“We’re thrilled to be the first to deliver an integrated solution based on our Merchant Map® and enhanced AI,” said Brian Longe, G2RS chief executive officer. “Our customers need to operate quickly and accurately to capture new merchant opportunities while also minimizing merchant portfolio risk. Speed is money, and our solution finally lets them scale up in a safe, smart way.”
Innovation to match evolution
As the e-commerce landscape expands with new online merchants and digital payment options, competition has increased. At the same time, regulations have gotten increasingly complex and punitive, and bad actors have become more sophisticated. Companies need innovation and agility to stay ahead in this ecosystem. Effective merchant onboarding is a critical step in the efficient setup of merchant clients for secure digital payment acceptance while avoiding exposure to fraud, card service rule infractions, and regulatory fines.
"The expanding e-commerce landscape presents exciting opportunities and significant challenges for the payments industry," said Rochelle Blease, G2RS president of merchant risk solutions. "Global Onboarding empowers financial institutions and other payments providers to navigate this dynamic environment confidently, acting swiftly on new business opportunities while minimizing exposure to illegal activity and non-compliance."
Combining the industry’s best resources
Global Onboarding incorporates advanced proprietary technology to enable rapid, confident merchant onboarding. The solution includes robust G2RS risk mitigation and business enablement capabilities that are unique within the payments industry, including:
- Merchant Map®, a proprietary, industry-exclusive merchant behavior database built over 20+ years with billions of data points, all validated by G2RS expert analysts.
- Compass Score®, a comprehensive, AI-driven score that predicts the risk of problematic merchant activity during the next 12 months. The scoring models synthesize data from the Merchant Map and additional data sources, including watchlists and sanctions registries, consumer ratings and adverse media, and risk-based insights for content compliance and operational risk.
- Merchant lifecycle risk management, a comprehensive approach covering risk from underwriting and onboarding to ongoing monitoring and transaction laundering detection, with re-underwriting as needed for audits or investigations.
"Our global customers need tools that keep pace with the increasing complexity and growth of the industry,” said Gavin Andrews, G2RS director of product management. “The AI-powered insights, comprehensive risk evaluations, and automation-ready workflows in Global Onboarding address the critical needs for efficiency, accuracy, and smarter decision-making when onboarding merchants. This is fintech that helps payments providers more confidently scale their operations.”
To learn more, visit g2risksolutions.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827954388/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom